Literature DB >> 22918623

Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?

F Wilford Germino1.   

Abstract

Since their introduction over 50 years ago thiazide and thiazide-like diuretics have been a mainstay in the treatment of hypertension. Yet despite outcome evidence with chlorthalidone, the preponderance of usage has been with hydrochlorothiazide-either as monotherapy or in combination with other drugs. There is an increasing debate as to whether or not there are significant differences between hydrochlorothiazide and chlorthalidone. Early outcome studies, upon which the recommendations were made, utilized higher doses than those not only commonly employed in clinical practice, but also studied in more recent outcome trials. In addition, data suggests that chlorthalidone may be more potent, in equal doses, in its BP response than hydrochlorothiazide. A fundamental question asked in the debate is whether or not the benefits attributed to chlorthalidone as a thiazide-like diuretic may be reasonably ascribed to thiazides given differences in their pharmacokinetic properties and perhaps some other more recently noted differences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918623     DOI: 10.1007/s11886-012-0307-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  32 in total

1.  Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials.

Authors:  Franz H Messerli; Harikrishna Makani; Alexandre Benjo; Jorge Romero; Carlos Alviar; Sripal Bangalore
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.

Authors:  Norman M Kaplan
Journal:  Hypertension       Date:  2011-10-24       Impact factor: 10.190

3.  Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.

Authors:  John B Kostis; Alan C Wilson; Ronald S Freudenberger; Nora M Cosgrove; Sara L Pressel; Barry R Davis
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

4.  Chlorthalidone versus hydrochlorothiazide as the preferred diuretic: is there a verdict yet?

Authors:  John M Flack; Domenic A Sica; Shawna Nesbitt
Journal:  Hypertension       Date:  2011-03-07       Impact factor: 10.190

5.  Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis.

Authors:  Ryan Woodman; Christina Brown; Warren Lockette
Journal:  Hypertension       Date:  2010-07-12       Impact factor: 10.190

6.  Antioxidative effects of thiazide diuretics in refractory hypertensive patients. A randomized crossover trial of chlortalidone and trichlormethiazide.

Authors:  Koichi Sato; Yasuaki Dohi; Masayoshi Kojima; Hiroyuki Takase; Shin Suzuki; Shigenori Ito
Journal:  Arzneimittelforschung       Date:  2010

Review 7.  Hydrochlorothiazide versus chlorthalidone in the management of hypertension.

Authors:  Kimberly M Neff; James J Nawarskas
Journal:  Cardiol Rev       Date:  2010 Jan-Feb       Impact factor: 2.644

8.  Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.

Authors:  Hiroshi Yamanari; Kazufumi Nakamura; Daiji Miura; Shuichi Yamanari; Tohru Ohe
Journal:  Clin Exp Hypertens       Date:  2009-10       Impact factor: 1.749

Review 9.  Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.

Authors:  Barry L Carter; Michael E Ernst; Jerome D Cohen
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

10.  Thiazide diuretics, endothelial function, and vascular oxidative stress.

Authors:  Ming-Sheng Zhou; Ivonne Hernandez Schulman; Edgar A Jaimes; Leopoldo Raij
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.